Premium
Ocular Therapeutix Inc (OCUL)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-04-09 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -394,70k | 0,00 | Other Disposition | - | 694,81k | -36,23% |
| 2026-02-23 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -20,06k | 166,06k | Vente | 8,28 | 623,56k | -3,12% |
| 2026-02-23 | Dr. Jeffrey S. HeierChief Scientific Officer | -3,06k | 25,31k | Vente | 8,28 | 177,59k | -1,69% |
| 2026-02-23 | Dr. Peter K. KaiserChief Development Officer | -2,81k | 23,27k | Vente | 8,28 | 52,03k | -5,12% |
| 2026-02-23 | Mr. Sanjay NayakChief Strategy Officer | -1,76k | 14,56k | Vente | 8,28 | 158,30k | -1,10% |
| 2026-02-20 | Dr. Nadia K. WaheedChief Medical Officer | -3,51k | 27,17k | Vente | 7,74 | 61,78k | -5,38% |
| 2026-02-20 | Dr. Richard L. LindstromIndependent Director | 60,23k | 461,35k | Achat | 7,66 | 232,93k | 34,87% |
| 2026-02-12 | Mr. Donald NotmanCFO, COO & Principal Accounting Officer (Leave of Absence) | -11,45k | 103,47k | Vente | 9,04 | 182,68k | -5,90% |
| 2026-02-12 | Mr. Sanjay NayakChief Strategy Officer | -10,35k | 93,55k | Vente | 9,04 | 160,05k | -6,07% |
| 2026-02-12 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -124,88k | 1,13M | Vente | 9,04 | 643,62k | -16,25% |
| 2026-02-12 | Dr. Nadia K. WaheedChief Medical Officer | -7,86k | 71,08k | Vente | 9,04 | 65,29k | -10,75% |
| 2026-02-02 | Mr. Donald NotmanCFO, COO & Principal Accounting Officer (Leave of Absence) | -11,49k | 101,40k | Vente | 8,54 - 9,14 | 155,79k | -6,87% |
| 2025-11-24 | Mr. Sanjay NayakChief Strategy Officer | -1,88k | 22,61k | Vente | 12,04 | 133,40k | -1,39% |
| 2025-11-24 | Dr. Peter K. KaiserChief Development Officer | -3,01k | 36,14k | Vente | 12,02 | 73,84k | -3,91% |
| 2025-11-24 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -19,53k | 235,14k | Vente | 12,04 | 351,84k | -5,26% |
| 2025-11-26 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -49,75k | 0,00 | Other Disposition | - | 351,84k | -12,39% |
| 2025-11-24 | Dr. Jeffrey S. HeierChief Scientific Officer | -3,47k | 41,77k | Vente | 12,04 | 128,35k | -2,63% |
| 2025-11-05 | Dr. Namrata SarojChief Business Officer | -25,87k | 277,79k | Vente | 10,74 | 174,14k | -12,93% |
| 2025-10-08 | Mr. Todd D.C. AndermanChief Legal Officer & Corporate Secretary | -11,13k | 137,37k | Vente | 12,34 | 87,57k | -11,28% |
| 2025-10-02 | Dr. Peter K. KaiserChief Development Officer | -9,65k | 106,47k | Vente | 11,03 | 66,66k | -12,65% |
| 2025-10-02 | Dr. Jeffrey S. HeierChief Scientific Officer | -10,50k | 115,94k | Vente | 11,04 | 121,63k | -7,95% |
| 2025-09-09 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -49,75k | 0,00 | Other Disposition | - | 300,12k | -14,22% |
| 2025-09-02 | Mr. Donald NotmanCFO, COO & Principal Accounting Officer (Leave of Absence) | -1,07k | 13,25k | Vente | 12,43 | 126,84k | -0,83% |
| 2025-08-25 | Dr. Peter K. KaiserChief Development Officer | -3,01k | 36,25k | Vente | 12,04 | 42,98k | -6,55% |
| 2025-08-25 | Mr. Sanjay NayakChief Strategy Officer | -1,89k | 22,70k | Vente | 12,04 | 128,59k | -1,44% |
| 2025-08-25 | Dr. Jeffrey S. HeierChief Scientific Officer | -3,06k | 36,88k | Vente | 12,04 | 98,80k | -3,01% |
| 2025-08-25 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -21,49k | 258,79k | Vente | 12,04 | 300,12k | -6,68% |
| 2025-04-28 | Dr. Pravin U. DugelExecutive Chairman, President & CEO | -250,36k | 0,00 | Other Disposition | - | 250,36k | -50,00% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
